Prostate Cancer

Dear Colleagues,

The prevalence of prostate cancer (PCa), in western countries, is extremely high and tends to increases with age. Statistics have shown that 1 in 6 men will be diagnosed with PCa during their lifetime. This disease is the leading cause of male cancer-related death, second only to lung cancer. Notwithstanding the sizable number of deaths, the majority of cases have indolent or slow growing tumors. In PCa, strategies for clinical decision-making and diagnosis are based on clinical examination, PSA-levels and histopathologic evaluation. However, their inaccuracy in a significant subset of patients results in an overtreatment in many men. The understanding of the cancer biology of patients suffering from Pca is key for making progress on the treatment of these patients. We would like to invite manuscripts relating to novel biomarker discovery and validation in PCa. We are also particularly interested in manuscripts deciphering the molecular and biochemical development and progression of PCa, as well as epidemiologic aspects related to PCa. This issue on the whole will focus on understanding prostate cancer at a molecular, biochemical and genetic level.

Thanks you for your collaboration.

Sven Perner
Guest Editor